CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
Delayed Nasdaq  -  05/16 03:49:00 pm EDT
25.12 USD   +5.09%
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Maintains Buy Rating
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Main..
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
05/10Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ende..
CI
05/10Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
AQ
04/18INSIDER SELL : Cerevel Therapeutics Holdings
MT
04/13Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update..
AQ
04/08SIRS 2022 PRESENTATION – EMRAC : Results From a Phase 1b Trial in Patients With Schi..
PU
04/06AAN 2022 POSTER - PHARMACOKINETICS, : Summary of Early Phase Clinical Studies
PU
04/06AAN 2022 PRESENTATION - DARIGABAT : pronounced antiepileptic activity in the mesial tempor..
PU
03/31Berenberg Bank Initiates Coverage on Cerevel Therapeutics Holdings With Buy Rating, $46..
MT
03/31Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
AQ
03/21INSIDER SELL : Cerevel Therapeutics Holdings
MT
03/21Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event
AQ
03/11INSIDER SELL : Cerevel Therapeutics Holdings
MT
03/01CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
03/01TRANSCRIPT : Cerevel Therapeutics Holdings, Inc., Q4 2021 Earnings Call, Mar 01, 2022
CI
03/01Cerevel Therapeutics' Q4 Loss Widens; Expects Higher Expenses in Full-Year 2022
MT
03/01CEREVEL THERAPEUTICS : Provides Update on Pipeline Progress along with Fourth Quarter and ..
PU
03/01Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter and..
CI
03/01Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and..
AQ
02/16Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Updat..
AQ
02/15TRANSCRIPT : Cerevel Therapeutics Holdings, Inc. - Special Call
CI
02/15Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinic..
AQ
02/15Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinic..
CI
02/15Goldman Sachs Starts Cerevel Therapeutics Holdings at Neutral With $27 Price Target
MT
02/14INSIDER SELL : Cerevel Therapeutics Holdings
MT
01/10TRANSCRIPT : Cerevel Therapeutics Holdings, Inc. Presents at JPMorgan 40th Annual Healthca..
CI
01/10CEREVEL THERAPEUTICS TO PRESENT AT 4 : Additional Details of Phase 2 Program for Emraclidi..
AQ
01/05JPMorgan Starts Cerevel Therapeutics Holdings at Overweight With $50 Price Target
MT
01/03Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021Cerevel Agrees Multi-year Collaboration With Herophilus to Research, Develop Therapeuti..
MT
2021HC Wainwright Starts Cerevel Therapeutics Holdings at Buy With $50 Price Target
MT
2021CVL-231 : Results From an Early Proof-Of-Concept Study in Patients With Schizophrenia
PU
2021CEREVEL THERAPEUTICS : Evaluation of M4 Muscarinic Receptor Occupancy by CVL-231 in Nonhum..
PU
2021Cerevel Therapeutics Corporate Presentation
PU
2021Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates ..
PU
2021CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
2021Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences
AQ
2021CEREVEL THERAPEUTICS : to Report Third Quarter 2021 Financial Results on Wednesday, Novemb..
AQ
2021CEREVEL THERAPEUTICS : Jefferies & Co Adjusts Cerevel Therapeutics Holdings PT to $37 From..
MT
2021CEREVEL THERAPEUTICS : R&D Day Presentation
PU
2021CEREVEL THERAPEUTICS : Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apath..
GL
2021Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apat..
CI
2021CEREVEL THERAPEUTICS : Announces Departure of CFO Kathy Yi (Form 8-K)
PU
2021CEREVEL THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers, Regulatio..
AQ
2021CEREVEL THERAPEUTICS : CFO Kathy Yi Steps Down; Mark Bodenrader Named Interim CFO
MT
2021CEREVEL THERAPEUTICS : Announces Departure of CFO Kathy Yi
AQ
2021Cerevel Therapeutics Holdings, Inc. Announces Executive Changes
CI
2021CEREVEL THERAPEUTICS : Morgan Stanley Adjusts Cerevel Therapeutics Holdings PT to $39 From..
MT
2021CEREVEL THERAPEUTICS : to Present at Upcoming Virtual Investor Conferences
AQ
2021CEREVEL THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2021CEREVEL THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Business Updates ..
PU
2021CEREVEL THERAPEUTICS : Corporate Presentation
PU
2021TRANSCRIPT : Cerevel Therapeutics Holdings, Inc., Q2 2021 Earnings Call, Aug 11, 2021
CI
2021CEREVEL THERAPEUTICS' : Q2 Loss Narrows, Operating Expenses Grow
MT
2021Cerevel Therapeutics Holdings, Inc. Reports Unaudited Consolidated Earnings Results for..
CI
2021CEREVEL THERAPEUTICS : Announces Redemption of Public Warrants (Form 8-K)
PU
2021CEREVEL THERAPEUTICS HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
2021CEREVEL THERAPEUTICS : Announces Redemption of Public Warrants
AQ
2021CEREVEL THERAPEUTICS : to Report Second Quarter 2021 Financial Results on Wednesday, Augus..
AQ
2021CEREVEL THERAPEUTICS : Stifel Adjusts Price Target on Cerevel Therapeutics Holdings to $33..
MT
2021CEREVEL THERAPEUTICS : Announces Pricing of $350 Million Public Offering of Common Stock (..
PU
2021CEREVEL THERAPEUTICS HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
2021CEREVEL THERAPEUTICS : Prices Common Stock Offering at $25 Per Share
MT
2021SECTOR UPDATE : Health Care Stocks Mostly Treading Water Near Wednesday Close
MT
2021CEREVEL THERAPEUTICS : Stock Drops 11% on Public Offering of 14 Million Shares
MT
2021SECTOR UPDATE : Health Care Stocks Slip as Biotechs Rally
MT
2021SECTOR UPDATE : Health Care
MT
2021CEREVEL THERAPEUTICS : to Sell 14 Million Shares in Public Offering
MT
2021SECTOR UPDATE : Health Care Stocks Still Listless Near Session's End
MT
2021SECTOR UPDATE : Health Care Stocks Managing Slight Gains
MT
2021SECTOR UPDATE : Health Care
MT
1  2  3Next
Upcoming event on CEREVEL THERAPEUTICS HOLDINGS, INC.